688293 Stock Overview
Provides cell culture media and CDMO services in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Shanghai OPM Biosciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥29.52 |
| 52 Week High | CN¥64.64 |
| 52 Week Low | CN¥26.30 |
| Beta | 0 |
| 11 Month Change | -1.17% |
| 3 Month Change | -25.66% |
| 1 Year Change | -43.52% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.52% |
Recent News & Updates
Shareholder Returns
| 688293 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 4.4% | 3.9% | 0.8% |
| 1Y | -43.5% | -23.8% | -21.0% |
Return vs Industry: 688293 underperformed the CN Biotechs industry which returned -23.8% over the past year.
Return vs Market: 688293 underperformed the CN Market which returned -21% over the past year.
Price Volatility
| 688293 volatility | |
|---|---|
| 688293 Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 5.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.9% |
Stable Share Price: 688293's share price has been volatile over the past 3 months.
Volatility Over Time: 688293's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 285 | Zhihua Xiao | www.opmbio.com |
Shanghai OPM Biosciences Co., Ltd. provides cell culture media and CDMO services in China and internationally. The company offers OPM cell culture media services, including OPM-CHO platform, OPM-293 platform, OPM-VAC platform, OPM-Hybri platform, and classical media; customized media solutions; and OEM media manufacturing services. It also provides end-to-end biologics CDMO services, such as antibody discovery, stable cell line development & cell banking platform, upstream process development, downstream process development, OPM formulation development platform, quality control and product characterization of biologics, and pilot scale production services.
Shanghai OPM Biosciences Co., Ltd. Fundamentals Summary
| 688293 fundamental statistics | |
|---|---|
| Market cap | CN¥3.36b |
| Earnings (TTM) | CN¥49.43m |
| Revenue (TTM) | CN¥254.91m |
68.0x
P/E Ratio13.2x
P/S RatioIs 688293 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688293 income statement (TTM) | |
|---|---|
| Revenue | CN¥254.91m |
| Cost of Revenue | CN¥105.15m |
| Gross Profit | CN¥149.76m |
| Other Expenses | CN¥100.33m |
| Earnings | CN¥49.43m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
| Earnings per share (EPS) | 0.43 |
| Gross Margin | 58.75% |
| Net Profit Margin | 19.39% |
| Debt/Equity Ratio | 0% |
How did 688293 perform over the long term?
See historical performance and comparison